MENU ABOUT US MAKE A DONATION
The Epoch Times
Login
SEARCH
CLOSE
Help Center subscribe newsletter Newsstands Epoch Shop Gift
  • TOP NEWS
  • SPECIAL SERIES
  • SPECIAL COVERAGE
  • LATEST ARTICLES
  • US
    • US News
    • US Features
    • US Politics
    • US Crime News
    • New York
    • San Francisco
    • Los Angeles
  • Opinion
    • Thinking About China
    • Viewpoints
    • Unbridled Evil: The Corrupt Reign of Jiang Zemin in China
    • The Reader’s Turn
  • China News
    • US-China Relations
    • Chinese Regime
    • Business & Economy
    • Chinese Culture
    • China Human Rights
    • Social Issues
    • Organ Harvesting in China
  • World News
    • Africa News
    • Americas
    • Asia & Pacific
    • Canada
    • Europe
    • UK News
    • Australia News
    • International
    • Middle East
  • Business & Markets
    • Companies
    • Economy
    • Markets
    • Real Estate
    • Gold and Commodities
  • ARTS & CULTURE
    • Fine Arts & Craftsmanship
    • Performing Arts
    • Books
    • Traditional Culture
    • Shen Yun Special Coverage
    • Film & TV
  • Science
    • News
    • Space
    • Environment
  • Tech
    • Tech News
    • Tech Products & Reviews
    • Social Media
  • Sports
  • Video
    • American Thought Leaders
    • China Insider
    • Crossroads
  • Bright
    • Lifestyle
    • Inspired
    • Family & Education
    • Personal Finance
    • American Essence
  • Entertainment
    • Film & TV
    • Entertainment News
  • Health
    • Experts
    • Conditions
    • Life & Wellness
  • Special Topics
    • Battlefields
SEARCH
  • EpochTV
  • US
  • US Politics
  • Opinion
  • World News
  • China
  • Hong Kong
  • Health
  • Bright
  • Arts
  • Falun Gong
  • Premium
  • Markets
  • Games
  • Livestream
  • More

COVID-19 antiviral

  • Study Links Merck’s COVID-19 Antiviral Pill to Mutated Strains
    Study Links Merck’s COVID-19 Antiviral Pill to Mutated Strains
    The findings published in the journal Nature suggests that molnupiravir may enable mutated viruses to spread.
    September 25, 2023BY Caden Pearson
  • US Begins Trials for Japanese COVID-19 Antiviral Drug Xocova
    US Begins Trials for Japanese COVID-19 Antiviral Drug Xocova
    The National Institutes of Health (NIH) is conducting a multi-site clinical trial to evaluate Shionogi & Co.’s Xocova ...
    February 16, 2023BY Naveen Athrappully
TOP NEWS
  • ‘All-American Halftime Show’ Serves as Alternative to Super Bowl’s Bad Bunny, Green Day Performance
    NEW By Jeff Louderback
    ‘All-American Halftime Show’ Serves as Alternative to Super Bowl’s Bad Bunny, Green Day Performance
  • Trump Endorses Nexstar–Tegna Broadcast Television Deal
    NEW By Jacob Burg
    Trump Endorses Nexstar–Tegna Broadcast Television Deal
  • Senator Says Savannah Guthrie Called Him Before Calling Police About Missing Mother
    1hr By Jack Phillips
    Senator Says Savannah Guthrie Called Him Before Calling Police About Missing Mother
  • Why Canada’s China Pivot Makes US Tariff Relief Harder
    2hr By Sean Tseng
    Why Canada’s China Pivot Makes US Tariff Relief Harder
  • Trump Meets With Honduran President Nasry Asfura in Florida
    3hr By Jacki Thrapp
    Trump Meets With Honduran President Nasry Asfura in Florida
  • Chinese Congress Sidesteps Purged Generals, Raising Questions About Xi’s Grip on Military: Insiders
    4hr By Michael Zhuang
    Chinese Congress Sidesteps Purged Generals, Raising Questions About Xi’s Grip on Military: Insiders
  • Takaichi’s Ruling Bloc Wins Landslide Election in Japan’s Lower House
    7hr By Jacob Burg
    Takaichi’s Ruling Bloc Wins Landslide Election in Japan’s Lower House
  • Blue Cities Dominate Affordable Housing Construction Surge
    8hr By Mary Prenon
    Blue Cities Dominate Affordable Housing Construction Surge
  • US Health Spending Explained in 5 Charts
    9hr By Lawrence Wilson
    US Health Spending Explained in 5 Charts
  • Myopia: 2 in 5 People Are Affected–Here’s How to Slow Progression
    9hr By Mercura Wang
    Myopia: 2 in 5 People Are Affected–Here’s How to Slow Progression
The Epoch Times
Copyright © 2000 - 2026 The Epoch Times Association Inc. All Rights Reserved.
Back Top